ARTICLE | Clinical News
Mydicar regulatory update
April 14, 2014 7:00 AM UTC
Celladon said FDA granted breakthrough therapy designation to Mydicar to reduce hospitalizations in patients with New York Heart Association (NYHA) class III/IV symptoms of heart failure (HF) who are ...